Literature DB >> 22241113

Human polyomaviruses JC and BK in the urine of Brazilian children and adolescents vertically infected by HIV.

Daisy Maria Machado1, Maria Cristina Fink, Cláudio Sérgio Pannuti, Regina Célia de Menezes Succi, Alessandra Aparecida Machado, Fabiana Bononi do Carmo, Aída de Fátima Barbosa Gouvêa, Paulo Roberto Urbano, Suenia Vasconcelos Beltrão, Isabel Cristina Lopes dos Santos, Clarisse Martins Machado.   

Abstract

The aim of this study was to characterize the urinary excretion of the BK (BKV) and JC (JCV) human polyomaviruses in a cohort of human immunodeficiency virus (HIV)-infected children and adolescents. One hundred and fifty-six patients were enrolled: Group I included 116 HIV-infected children and adolescents [median age = 11.4 years (y); range 1-22 y]; Group II included 40 non-HIV-infected healthy controls (median age = 11.37 y; range 7-16 y). Single urine samples from both groups were screened for the presence of JCV and BKV DNA by polymerase chain reaction at enrolment. The overall rate of JCV and BKV urinary excretion was found to be 24.4% and 40.4%, respectively (n = 156). Group I had urinary excretion of JCV and BKV in 27.6% and 54.3% of subjects, respectively. In contrast, Group II showed positive results for JCV in 17.5% of subjects and for BKV in 12.5% of subjects (p Pearson JCV = 0.20; p Pearson BKV < 0.0001). In Group I, there was no association between JCV/BKV shedding and age, gender or CD4 values. Patients with an HIV viral load < 50 copies/mL had a lower excretion of BKV (p < 0.001) and a trend of lower JCV excretion (p = 0.07). One patient in Group I (1/116, 0.9%) showed clinical and radiological features consistent with progressive multifocal leukoencephalopathy, suggesting that children with HIV/polyomavirus coinfection should be kept under surveillance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22241113     DOI: 10.1590/s0074-02762011000800006

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

1.  Molecular characterization of BK virus in patients infected with human immunodeficiency virus.

Authors:  Danijela Karalic; Ivana Lazarevic; Ana Banko; Maja Cupic; Djordje Jevtovic; Tanja Jovanovic
Journal:  Med Microbiol Immunol       Date:  2015-10-26       Impact factor: 3.402

2.  Human polyomavirus KI, WU, BK, and JC in healthy volunteers.

Authors:  Giselle P A Pena; Gabriella S Mendes; Helver G Dias; Lucas S Gavazzoni; Ariane R Amorim; Norma Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-18       Impact factor: 3.267

3.  The prevalence and isolated subtypes of BK polyomavirus reactivation among patients infected with human immunodeficiency virus-1 in southeastern China.

Authors:  Caiqin Hu; Ying Huang; Juwei Su; Mengyan Wang; Qihui Zhou; Biao Zhu
Journal:  Arch Virol       Date:  2018-02-12       Impact factor: 2.574

4.  Detection and analysis of variants of JC polyomavirus in urine samples from HIV-1-infected patients in China's Zhejiang Province.

Authors:  Caiqin Hu; Ying Huang; Junwei Su; Mengyan Wang; Qihui Zhou; Biao Zhu
Journal:  J Int Med Res       Date:  2018-01-11       Impact factor: 1.671

5.  Polyomavirus in saliva of HIV-infected children, Brazil.

Authors:  Tatiana F Robaina; Gabriella S Mendes; Fabrício J Benati; Giselle A Pena; Raquel C Silva; Miguel A R Montes; Renata Otero; Gloria F Castro; Fernando P Câmara; Norma Santos
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

Review 6.  BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection.

Authors:  Darlene Vigil; Nikifor K Konstantinov; Marc Barry; Antonia M Harford; Karen S Servilla; Young Ho Kim; Yijuan Sun; Kavitha Ganta; Antonios H Tzamaloukas
Journal:  World J Transplant       Date:  2016-09-24

7.  Prevalence of Human Polyomavirus JC and BK in Normal Population.

Authors:  Lila Karimi Dehcheshmeh; Manoochehr Makvandi; Ali Timori
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.